Journal Article

Incidence of Carbapenem-Associated Allergic-Type Reactions among Patients with versus Patients without a Reported Penicillin Allergy

William A. Prescott, Daryl D. DePestel, Jeffrey J. Ellis and Randolph E. Regal

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 38, issue 8, pages 1102-1107
Published in print April 2004 | ISSN: 1058-4838
Published online April 2004 | e-ISSN: 1537-6591 | DOI: https://dx.doi.org/10.1086/382880
Incidence of Carbapenem-Associated Allergic-Type Reactions among Patients with versus Patients without a Reported Penicillin Allergy

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

This retrospective analysis sought to determine the comparative incidence of cross-reactivity associated with carbapenem antibiotic treatment among patients with versus those without penicillin allergy. We sought to determine whether the incidence of cross-reactivity is different between imipenem-cilastatin and meropenem. A total of 211 patients were treated with a carbapenem antibiotic. Included were 100 patients with and 111 patients without a documented or reported penicillin allergy. Within each group, subgroups of penicillin-allergic and penicillin-nonallergic patients were balanced equally between imipenem-cilastatin and meropenem. The incidence of patients with a reported or documented penicillin allergy experiencing an allergic-type reaction to a carbapenem was 11%, which is 5.2 times greater than the risk in patients who were reportedly not allergic to penicillin (P = .024). No difference in the occurrence of allergic-type reactions was observed between the 2 carbapenems.

Journal Article.  2896 words.  Illustrated.

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.